Attention Deficit Hyperactivity Disorder Clinical Trial
Official title:
Formulation-Based Cognitive-Behavioral Therapy Compared to an Active Control and a Waitlist in Adult Inmates With ADHD: A Randomized Controlled Trial
Background Recent literature suggests that ADHD is a risk factor for the development of antisocial behavior that is more severe and persistent than in community and other psychiatric populations. The combination of stimulant medication and psychotherapy (particularly cognitive-behavioral therapy, CBT) is considered an evidence-based intervention for adults with ADHD. In contrast, few studies have evaluated the efficacy of medication in adult prisoners with ADHD, and the literature on the efficacy of psychotherapy is virtually nonexistent. Therefore, this article presents the protocol of a trial that will assess the efficacy of a formulation-based CBT program for inmates with ADHD. Methods The study has a multicenter randomized controlled trial design. After screening and recruitment, participants will be randomly assigned to the CBT intervention, a general offender treatment program, or a waitlist. Pre- and post-treatment self-report and clinician-report assessments, as well as 6- and 12-month follow-up assessments will be conducted. These will include both clinical (e.g., ADHD symptoms, depression and anxiety symptoms, self-esteem, alcohol/drug abuse, treatment adherence, quality of life) and criminological (e.g., recidivism and risk of recidivism) measures. Linear mixed models will be used to assess differences between groups. Discussion This study may be the first to evaluate the efficacy of a psychotherapy intervention in adult inmates with ADHD. It is expected that addressing the specific needs of ADHD would not only result in the previously reported clinical improvements (e.g., reduction in ADHD and comorbidity symptoms), but also reduce the risk and rate of recidivism compared to the general intervention or no intervention. However, the design may be limited by the difficulties inherent in the prison setting and in following up the sample after release.
Status | Not yet recruiting |
Enrollment | 111 |
Est. completion date | September 2026 |
Est. primary completion date | September 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - To have signed written informed consent to participate in the study - To be between 18 and 65 years of age - To meet the DSM-5 diagnostic criteria for ADHD (American Psychiatric Association, 2013) - To have been convicted of at least one crime under Spanish or German criminal law - To have been incarcerated for at least six months and three or fewer years since the completion of the conviction at the time of eligibility assessment. Exclusion Criteria: - To have a severe personality disorder, psychotic disorder, or pervasive developmental disorder as their primary diagnosis, as the intervention would not meet their clinical needs - To have an IQ of 80 or less, as measured by a standardized IQ test (Raven et al., 1993), due to the complexity of the cognitive components in the CBT program - To have participated in a previous psychological intervention for ADHD; - To not be fluent in Spanish or German, depending on the study site. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Universidad Europea de Valencia |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Treatment adherence | In order to measure adherence more objectively, attendance at treatment sessions and completion of homework assignments are systematically recorded by the therapist at each session. | During the intervention | |
Primary | Conners Adult ADHD Diagnostic Interview for DSM-IV (CAADID) | This is considered one of the primary outcomes. The CAADID is a structured interview divided into two parts. Part I may be self-administered or clinician-administered and collects information on the subject's demographic history, developmental history, associated risk factors, and comorbidity, while Part II must be administered by a trained clinician and assesses DSM-IV criteria for ADHD in adults. Only Part II will be used for the study, as information on patient history is not relevant for measuring response to interventions. | Pre and post-treatment plus follow-up assessments 6 and 12 months after the end of the intervention | |
Primary | Reoffending rate | This will be the primary criminological outcome. Police records will be checked every 6 months after the end of treatment to look for new arrests. We will also try to check court and prison records for new convictions and incarcerations. However, access to this information may be very limited in European criminal justice systems, so it may be difficult to obtain. | Pre and post-treatment plus follow-up assessments 6 and 12 months after the end of the intervention | |
Secondary | Clinical Global Impression (CGI) | Is a three-item observer-rated scale that measures illness severity, global improvement or change, and therapeutic response. It is a widely used, robust measure of efficacy in clinical trials. The global functioning outcome provides a measure of the impact that symptoms have on daily functioning in life domains (e.g., social, family, work, personal, and academic, among others). | Pre and post-treatment plus follow-up assessments 6 and 12 months after the end of the intervention | |
Secondary | Attention-deficit/hyperactivity rating scale-IV | This measure will be the primary self-reported outcome. The scale includes 18 items that reference DSM-IV criteria (American Psychiatric Association, 2000), and it is used to determine the presence and severity of current ADHD symptoms. Each item is scored from 0 (never, rarely) to 3 (often). This measure has high validity and reliability and has been widely used both for clinical and research purposes. | Pre and post-treatment plus follow-up assessments 6 and 12 months after the end of the intervention | |
Secondary | Rosenberg self-esteem scale (RSES | This 10-item scale provides a unidimensional measure of global self-esteem and acceptance of self-worth. | Pre and post-treatment plus follow-up assessments 6 and 12 months after the end of the intervention | |
Secondary | Adult ADHD Quality of Life Questionnaire (AAQoL | It is an ecologically valid measure of the quality of life designed specifically for adults with ADHD. It consists of 29 items corresponding to four domains particularly relevant for patients with ADHD: productivity, psychological health, social relationships, and life perspectives. | Pre and post-treatment plus follow-up assessments 6 and 12 months after the end of the intervention | |
Secondary | Maudsley Addiction Profile (MAP) | This is a 60-item, multidimensional instrument for assessing treatment outcome in people with drug and/or alcohol problems. | Pre and post-treatment plus follow-up assessments 6 and 12 months after the end of the intervention | |
Secondary | Beck depression inventory-II (BDI-II) and Beck anxiety inventory (BAI) | These are one of the most commonly used self-report instruments to assess the severity of depressive and anxiety symptoms, respectively. A total score is obtained from the sumo of its 21 items, with higher scores indicating higher levels of depression or anxiety. | Pre and post-treatment plus follow-up assessments 6 and 12 months after the end of the intervention | |
Secondary | Historical Clinical Risk Management-20 (HCR-20) | This instrument is a guide to predicting violence risk in inmates and psychiatric patients, providing a probabilistic prediction of the risk of future antisocial behavior. A trained rater must assess the presence of 20 past, present, and future risk factors organized into three different scales. The HCR-20 includes both dynamic and static risk factors. Three levels of risk can be identified without initial reference to explicit tables, scales, or cutoff points: low, moderate, or high (and imminent). | Pre and post-treatment plus follow-up assessments 6 and 12 months after the end of the intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06129396 -
Effects of Aerobic Exercise Intervention in Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD)
|
N/A | |
Completed |
NCT04779333 -
Lifestyle Enhancement for ADHD Program 2
|
N/A | |
Recruiting |
NCT05935722 -
Evaluation of a Home-based Parenting Support Program: Parenting Young Children
|
N/A | |
Completed |
NCT03148782 -
Brain Plasticity Underlying Acquisition of New Organizational Skills in Children-R61 Phase
|
N/A | |
Completed |
NCT04832737 -
Strength-based Treatment Approach for Adults With ADHD
|
N/A | |
Recruiting |
NCT04631042 -
Developing Brain, Impulsivity and Compulsivity
|
||
Recruiting |
NCT05048043 -
Development of a Game-supported Intervention
|
N/A | |
Completed |
NCT03337646 -
Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism
|
Phase 4 | |
Not yet recruiting |
NCT06454604 -
Virtual Reality Treatment for Emerging Adults With ADHD
|
Phase 2 | |
Not yet recruiting |
NCT06406309 -
Settling Down for Sleep in ADHD: The Impact of Sensory and Arousal Systems on Sleep in ADHD
|
N/A | |
Completed |
NCT02477280 -
Effects of Expectation, Medication and Placebo on Objective and Self-rated Performance
|
Phase 4 | |
Completed |
NCT02911194 -
a2 Milk for Autism and Attention-deficit Hyperactivity Disorder (ADHD)
|
N/A | |
Completed |
NCT02829970 -
Helping College Students With ADHD Lead Healthier Lifestyles
|
N/A | |
Completed |
NCT02555150 -
A Comparison of PRC-063 and Lisdexamfetamine in the Driving Performance of Adults With ADHD
|
Phase 3 | |
Completed |
NCT02473185 -
Effects of Expectation, Medication and Placebo on Objective and Self-rated Performance During the QbTest
|
Phase 4 | |
Completed |
NCT02390791 -
New Technologies to Help Manage ADHD
|
N/A | |
Completed |
NCT02780102 -
Cognitive-Motor Rehabilitation, Stimulant Drugs, and Active Control in the Treatment of ADHD
|
N/A | |
Recruiting |
NCT04296604 -
Transcranial Direct Current Stimulation (tDCS) Neuromodulation of Executive Function Across Neuropsychiatric Populations
|
N/A | |
Recruiting |
NCT04175028 -
Neuromodulation of Executive Function in the ADHD Brain
|
N/A | |
Completed |
NCT02251080 -
Attention Deficit/Hyperactivity Disorder Internet Survey Study in a College Student Population
|
N/A |